{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:00Z","timestamp":1786119600299,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/coc.0b013e3181ec5f4b","type":"journal-article","created":{"date-parts":[[2010,10,2]],"date-time":"2010-10-02T06:44:08Z","timestamp":1286001848000},"page":"488-493","source":"Crossref","is-referenced-by-count":32,"title":["Multidrug Resistance Gene (MDR-1) and Risk of Brain Metastasis in Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer"],"prefix":"10.1097","volume":"34","author":[{"given":"Koji","family":"Matsuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele L.","family":"Eno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward H.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian M.K.","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight D.","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil B.","family":"Rosenshein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210128","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008.","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"issue":"suppl 1","key":"R2-9-20210128","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0020-7292(03)90118-4","article-title":"Carcinoma of the ovary.","volume":"83","author":"Heintz","year":"2003","journal-title":"Int J Gynaecol Obstet"},{"key":"R3-9-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"R4-9-20210128","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1067\/S0002-9378(03)00629-X","article-title":"Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy.","volume":"189","author":"Loizzi","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R5-9-20210128","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1200\/JCO.2002.20.4.982","article-title":"Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence.","volume":"20","author":"Kolomainen","year":"2002","journal-title":"J Clin Oncol"},{"key":"R6-9-20210128","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1136\/ijgc-00009577-200605000-00007","article-title":"Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy.","volume":"16","author":"Kastritis","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"R7-9-20210128","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1525-1438.2005.00143.x","article-title":"Brain metastases from epithelial ovarian cancer.","volume":"15","author":"Tay","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"R8-9-20210128","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1046\/j.1525-1438.2000.010005366.x","article-title":"Brain metastases from epithelial ovarian carcinoma.","volume":"10","author":"Kaminsky-Forrett","year":"2000","journal-title":"Int J Gynecol Cancer"},{"key":"R9-9-20210128","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1006\/gyno.2002.6653","article-title":"Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases.","volume":"85","author":"Anupol","year":"2002","journal-title":"Gynecol Oncol"},{"key":"R10-9-20210128","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1023\/B:NEON.0000014516.04943.38","article-title":"Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome.","volume":"66","author":"Cohen","year":"2004","journal-title":"J Neurooncol"},{"key":"R11-9-20210128","first-page":"563","article-title":"Cerebral metastasis from ovarian cancer treated with a multidisciplinary approach: case report and review of literature.","volume":"24","author":"Porzio","year":"2003","journal-title":"Eur J Gynecol Oncol"},{"key":"R12-9-20210128","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/j.1525-1438.2007.00941.x","article-title":"Prognostic factors associated with brain metastases from epithelial ovarian carcinoma.","volume":"17","author":"Kim","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"R14-9-20210128","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0090-8258(03)00060-X","article-title":"Surgical resection of solitary brain metastasis from ovarian carcinoma: an analysis of 22 cases.","volume":"89","author":"Cormio","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R15-9-20210128","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1525-1438.2007.01011.x","article-title":"Extent of extracranial disease is a powerful predictor of survival in patients with brain metastases from gynecological cancer.","volume":"18","author":"Growdon","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"R17-9-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R18-9-20210128","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/0959-8049(96)00057-3","article-title":"P-glycoproteina mediator of multidrug resistance in tumour cells.","volume":"32A","author":"Germann","year":"1996","journal-title":"Eur J Cancer"},{"key":"R19-9-20210128","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance.","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu Rev Med"},{"key":"R20-9-20210128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1006\/gyno.2002.6738","article-title":"Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer.","volume":"86","author":"Kamazawa","year":"2002","journal-title":"Gynecol Oncol"},{"key":"R21-9-20210128","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1525-1438.2006.00752.x","article-title":"Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer.","volume":"17","author":"Naniwa","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"R22-9-20210128","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/ijgc-00009577-200311000-00008","article-title":"Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer.","volume":"13","author":"Ikeda","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"R23-9-20210128","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1002\/ijc.24654","article-title":"Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.","volume":"125","author":"Matsuo","year":"2009","journal-title":"Int J Cancer"},{"key":"R25-9-20210128","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1158\/1078-0432.CCR-08-0606","article-title":"ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxelcarboplatin chemotherapy.","volume":"14","author":"Johnatty","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R26-9-20210128","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0169-409X(02)00172-2","article-title":"Drug efflux transporters in the CNS.","volume":"55","author":"Sun","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"R27-9-20210128","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/1097-0142(19880115)61:2<334::AID-CNCR2820610224>3.0.CO;2-M","article-title":"Prognostic significance of DNA index, multiploidy, and S-phase fraction in ovarian cancer.","volume":"61","author":"Kallioniemi","year":"1988","journal-title":"Cancer"},{"key":"R28-9-20210128","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00404-009-1121-1","article-title":"Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas.","volume":"281","author":"Matsuo","year":"2010","journal-title":"Arch Gynecol Obstet"},{"key":"R29-9-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ygyno.2005.03.042","article-title":"Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line.","volume":"98","author":"Hua","year":"2005","journal-title":"Gynecol Oncol"},{"key":"R30-9-20210128","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00280-008-0790-y","article-title":"Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells.","volume":"63","author":"Yadav","year":"2009","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/COC.0b013e3181ec5f4b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:41:04Z","timestamp":1786041664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-201110000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e3181ec5f4b","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}